Skip to main content
main-content

The independent medical news service

Kidney cancer

31-07-2019 | Oncology | News | Article

Durable survival with nivolumab in patients with advanced RCC, NSCLC

Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.

01-07-2019 | Oncology | News | Article

Targeted therapy can benefit complex patients with advanced RCC

Targeted therapy improves survival over nontargeted therapy among patients with metastatic renal cell carcinoma, including those who are older and have disabilities, shows an analysis of real-world data.

26-06-2019 | Oncology | News | Article

Nivolumab has ‘limited’ CNS activity in RCC patients with brain metastases

In patients with clear cell renal cell carcinoma and untreated central nervous system metastases, intracranial response to nivolumab monotherapy is restricted to those with a limited tumor burden, suggest phase II findings.

25-06-2019 | Oncology | News | Article

JAVELIN Renal 101 biomarker analysis may help personalize patient care

Biomarker analysis has given fresh insight into the response achieved with avelumab plus axitinib among advanced renal cell carcinoma patients participating in the JAVELIN Renal 101 trial.

18-06-2019 | Oncology | News | Article

Sarcomatoid RCC patients benefit from immune checkpoint inhibitor therapy

Subgroup analysis of the IMmotion151 trial suggests improved survival with first-line atezolizumab plus bevacizumab versus sunitinib for locally advanced or metastatic renal cell carcinoma patients with sarcomatoid differentiation.

09-06-2019 | Oncology | Main feed | News

KEYNOTE-426 subgroup analyses confirm pembrolizumab–axitinib efficacy

Research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, adds support for use of pembrolizumab plus axitinib  as a first-line treatment for patients with metastatic renal cell carcinoma.

17-05-2019 | Oncology | News | Article

USA approves first-line avelumab–axitinib for advanced RCC

Click through to read more

29-04-2019 | Oncology | News | Article

FDA approves first-line pembrolizumab–axitinib for advanced RCC

Click through to read more

05-03-2019 | Kidney cancer | News | Article

Cabozantinib efficacy extends to non-clear-cell RCC

Almost three-quarters of patients with non-clear-cell renal cell carcinoma may benefit from treatment with the tyrosine kinase receptor inhibitor cabozantinib, suggesting its efficacy is not limited to clear-cell disease, say researchers.

21-02-2019 | Kidney cancer | News | Article

Immunotherapy-based regimens show promise in non-clear-cell RCC

Three trials point to the potential of regimens incorporating agents targeting the programmed cell death protein 1 or its ligand in patients with non-clear-cell renal cell carcinoma.

20-02-2019 | Kidney cancer | News | Article

Tivozanib improves refractory advanced RCC outcomes

The phase III TIVO-3 trial has found that both progression-free survival and response are significantly better with tivozanib than sorafenib in patients with refractory metastatic renal cell carcinoma.

19-02-2019 | Kidney cancer | News | Article

Pembrolizumab–axitinib boosts untreated advanced RCC survival

Overall survival is significantly improved with the first-line combination of pembrolizumab and axitinib relative to sunitinib in patients with advanced renal cell carcinoma, shows the KEYNOTE-426 trial.

01-02-2019 | Colorectal cancer | News | Article

EMA gives biosimilar bevacizumab positive opinion

Read more on this decision here

24-01-2019 | Kidney cancer | News | Article

HRQoL greater with nivolumab plus ipilimumab than sunitinib in advanced RCC

Patients with previously untreated intermediate- or poor-risk advanced renal cell carcinoma derive greater health-related quality of life benefits from nivolumab plus ipilimumab than from sunitinib, CheckMate 214 data show.

21-01-2019 | Kidney cancer | News | Article

Sustained benefit of VEGFR–TKIs after doublet immunotherapy in metastatic RCC

Second-line treatment with vascular endothelial growth factor receptor–tyrosine kinase inhibitors after failure of nivolumab plus ipilimumab continues to benefit patients with metastatic renal cell carcinoma, report researchers.

18-01-2019 | Kidney cancer | News | Article

Potential ‘risk of harm’ for older women with adjuvant sunitinib for RCC

Adjuvant treatment with sunitinib may be associated with an increased mortality risk for older female patients with renal cell carcinoma, suggests a post-hoc analysis of the ASSURE trial that compared sunitinib and sorafenib with placebo.

11-01-2019 | Oncology | News | Article

Concomitant TKI–PPI use may adversely affect cancer patient survival

Taking proton pump inhibitors alongside tyrosine kinase inhibitors is associated with an increased mortality risk in older cancer patients, research indicates.

15-11-2018 | Oncology | News | Article

Genomic annotation improves MSKCC risk model for renal carcinoma

Adding the mutation status of three genes linked to renal cell carcinoma improves the prognostic value of the Memorial Sloan Kettering Cancer Center risk model for patients receiving tyrosine kinase inhibitors for metastatic disease, research shows.

26-10-2018 | Oncology | News | Article

First-line avelumab–axitinib outperforms sunitinib in advanced RCC

Results of the JAVELIN Renal 101 trial indicate that patients with a new diagnosis of advanced renal cell carcinoma have better outcomes when treated with the combination of avelumab and axitinib than with sunitinib.

13-07-2018 | Kidney cancer | News | Article

Germline mutations detected in advanced RCC patients

Germline mutations may be common in patients with advanced renal cell carcinoma and may have the potential to guide therapy if detected, US researchers report.

Image Credits